MétaCan
Menu
← Back to cohort

Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span.

2025· article· en· W4410810717 on OpenAlexaff
Scott Strum, Carlos Diego Holanda Lopes, Jeffrey N. Bruce, Omer Tirosh, Gal Dinstag, Saugato Rahman Dhruba, Danh-Tai Hoang, Tuvik Beker, Eldad D. Shulman, Anna Spreafico, Philippe L. Bédard, Sofia Genta, Albiruni Ryan Abdul Razak, Lillian L. Siu, Ranit Aharonov, Changsu Lawrence Park

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsPrincess Margaret Cancer CentreUniversity of TorontoQueen's UniversityUniversity Health Network
Fundersnot available
KeywordsMedicineBlockadeImmune checkpointOncologyInternal medicineReceptor

Abstract

fetched live from OpenAlex

2632 Background: Advanced computational AI algorithms, such as ENLIGHT and DeepPT (Med 2023, Nature Cancer 2024), represent a promising approach to identify predictive biomarkers for cancer therapeutics. Evaluation of ICB response prediction via these algorithms through the full span of pre-treatment, on-treatment, and at progression time points provides a dynamic perspective of response prediction abilities. Methods: A post-hoc analysis of two pan-cancer clinical trials was performed: i) BIO2 is a biobanking protocol of ICB-naïve patients (pts) treated with pembrolizumab (NCT02644369); and ii) The IRIS study (NCT04243720) which enrolled pts who have progressed immediately post ICB. In BIO2, complete, partial response or stable disease for >6 months was classified as responders (R), the rest as non-responders (NR). In IRIS, acquired and primary resistance were defined according to trial protocol. ENLIGHT matching scores were calculated using either transcriptomics from NGS (EMS-NGS), or transcriptomics imputed directly from H&E slides using DeepPT (EMS-DP). The predictive value of EMS was compared to PD-L1 IHC, tumor mutational burden (TMB) and tumor infiltrating lymphocytes (TILs) abundance by IHC, and its trajectory across timepoints was studied. Results: 76 pts from BIO2 (23:53, R:NR), and 37 pts from IRIS (18:19, AR:PR), comprising of 14 tumor types, were analyzed. We first established the value of ENLIGHT as a predictive biomarker using the BIO2 pre-treatment samples. EMS-NGS was a superior predictive biomarker compared with PD-L1 IHC, TMB and TIL abundance, while EMS-DP was comparable (Table). The EMS-NGS scores of responders were significantly higher than non-responders pre-treatment (medians: 0.92 vs. 0.62, p = 1.4e-4). Analyzing the trajectory of the EMS-NGS scores across two additional timepoints reveals that while the scores of non-responding patients remained low (median: 0.62, 0.69, 0.67 for pre-, on–treatment and post-progression, respectively), it is higher among responders (median: 0.92, 0.78 for pre- and on–treatment, respectively). Finally, EMS-NGS was higher among pts with acquired vs primary resistance in IRIS (medians: 0.75 vs 0.59, p = 0.17). Conclusions: In two pan-cancer cohorts, EMS-NGS outperformed conventional biomarkers in predicting ICB response. EMS-DP was comparable to conventional biomarkers and could be calculated directly from H&E slides in a fast, low-cost manner. EMS-NGS values were concordant with response or resistance throughout the ICB treatment course, reflecting the level of the tumor’s vulnerability to ICB inhibition. Further validation of ENLIGHT in larger ICB-treated pts is warranted given these promising results. Clinical trial information: NCT02644369 , NCT04243720 . ROC AUC (p) Sensitivity PPV (cf 30% baseline response rate) F1 Score EMS-NGS 0.74 (0.0003) 61 48 54 EMS-DP 0.64 (0.02) 57 45 50 PD-L1 IHC 0.7 (0.003) 70 40 51 TMB 0.64 (0.03) 39 69 50 TILs 0.6 (0.065) 39 52 44

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.006
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.061
GPT teacher head0.460
Teacher spread0.399 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→